Research point
tumour, Cancer
ADVERSE EVENT, DISEASE, SECONDARY, TUMOUR, CANCER
The primary endpoint of the study was to assess the efficacy of durvalumab with anlotinib as maintenance therapy in terms of median progression‐free survival (PFS, from randomization); secondary endpoint was OS and PFS (from diagnosis), objective response rate (ORR); disease control rate (DCR) and duration of response (DOR), safety and tolerability assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The exploratory endpoint of the study was to investigate potential biomarker based on peripheral blood and tumour tissue.